In a 30-year simulation for Chinese patients with T2DM, total direct medical costs were lower with metformin plus liraglutide than with metformin plus exenatide.
In plain wordsIn a computer model of type 2 diabetes care in China, metformin with liraglutide cost less than metformin with exenatide.
- Peptide
- Liraglutide
- Outcome
- DecreaseTotal direct medical costs
- Study
humann: not reported in source
CORE Diabetes Model simulation using data from patients with T2DM at one Chinese hospital- Comparator
- Metformin plus exenatide
- Outcome group
- Cost-effectiveness · Whole body
- Studied dose
- 0.6 mg/day, increased weekly to 1.2 or 1.8 mgAs given in this study (human).
Measurements
- Difference in total direct medical costs
- 2130 RMB/QALY yearly
- liraglutide lower than exenatide
Source sentences
The 30-year simulation showed that the total direct medical costs were lower using liraglutide compared to exenatide by 2130 RMB/QALY yearly, while the expected life expectancy and QALY were increased by 0.471 years and 0.388, respectively, using liraglutide with an incremental cost-effectiveness of -11,550 RMB/QALYs.
2 context sentences(design, population, supporting numbers)
Patients with T2DM from the Third Hospital of Hebei Medical University were treated with oral metformin combined with liraglutide (0.6 mg/day, could be increased by 0.6 mg weekly until 1.2 or 1.8 mg) or exenatide (5 μg bid for four weeks, increased to 10 μg bid).
The computer simulation model CORE was used to calculate the 30-year expected life expectancy, quality-adjusted life years (QALY), direct costs, HbA1c levels, body mass index (BMI), and the incidence of cardiovascular, renal, and ocular complications of T2DM.